Latest Tax Rebates News

Neurizon Therapeutics has locked in a $6 million cash rebate from the Australian Government’s R&D Tax Incentive, underpinning its upcoming HEALEY ALS Platform Trial with first patient dosing slated for early 2026.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

AdAlta Limited has aligned its AdCella manufacturing strategy with new US FDA guidelines, made a significant milestone payment to Shanghai Cell Therapy Group, and secured an additional R&D tax rebate, marking key progress in its cellular immunotherapy pipeline.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Great Dirt Resources has confirmed high-grade manganese mineralisation in NSW and identified 24 new exploration targets through advanced R&D techniques, supported by a $315k tax rebate and a strong cash position.

DataWorks Group has reported a robust turnaround with a $1.1 million positive operating cash flow in Q2 FY26, underpinned by major government contracts and validated social impact from its BetStop™ platform.

Latrobe Magnesium Limited has received a $6.29 million R&D tax rebate from the ATO, using the funds to reduce debt and progress its magnesium production plants in Australia and Malaysia.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.